Cholesterol Lowering Drug Market by Disease Type (Cardiovascular Diseases, Hypercholesterolemia, Hyperlipidemia), Class of Drug (Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations), Distribution Channels - Global Forecast 2024-2030

Cholesterol Lowering Drug Market by Disease Type (Cardiovascular Diseases, Hypercholesterolemia, Hyperlipidemia), Class of Drug (Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations), Distribution Channels - Global Forecast 2024-2030


The Cholesterol Lowering Drug Market size was estimated at USD 22.00 billion in 2023 and expected to reach USD 23.80 billion in 2024, at a CAGR 8.30% to reach USD 38.45 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cholesterol Lowering Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cholesterol Lowering Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cholesterol Lowering Drug Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Anant Pharmaceuticals Pvt. Ltd., AstraZeneca PLC, Bristol-Myers Squibb Company, Covis Pharma GmbH, Daiichi Sankyo Co., Ltd., Dr. Reddy’s Laboratories Ltd., Kowa Company, Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage


This research report categorizes the Cholesterol Lowering Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

Disease Type
Cardiovascular Diseases
Hypercholesterolemia
Hyperlipidemia
Class of Drug
Cholesterol Absorption Inhibitors
Fibrates
Fixed-Dose Combinations
Ion Exchange Resins
Novel Cholesterol-Lowering Drugs
PCSK9 Inhibitors
Statins
Distribution Channels
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cholesterol Lowering Drug Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cholesterol Lowering Drug Market?
3. What are the technology trends and regulatory frameworks in the Cholesterol Lowering Drug Market?
4. What is the market share of the leading vendors in the Cholesterol Lowering Drug Market?
5. Which modes and strategic moves are suitable for entering the Cholesterol Lowering Drug Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cholesterol Lowering Drug Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising burden of LDL cholesterol across the globe
5.1.1.2. Growing geriatric population with cholesterol complications
5.1.1.3. Increase in smoking and alcohol consumption escalate the risk of high cholesterol
5.1.2. Restraints
5.1.2.1. Severe side effects of statins causing rhabdomyolysis
5.1.3. Opportunities
5.1.3.1. Government investment toward the strengthening healthcare infrastructure
5.1.3.2. Development of drug formulation and emergence of new therapies such as emergence of PCSK9 inhibitors
5.1.4. Challenges
5.1.4.1. Availability of generic drugs of leading brands and stringent approvals process
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cholesterol Lowering Drug Market, by Disease Type
6.1. Introduction
6.2. Cardiovascular Diseases
6.3. Hypercholesterolemia
6.4. Hyperlipidemia
7. Cholesterol Lowering Drug Market, by Class of Drug
7.1. Introduction
7.2. Cholesterol Absorption Inhibitors
7.3. Fibrates
7.4. Fixed-Dose Combinations
7.5. Ion Exchange Resins
7.6. Novel Cholesterol-Lowering Drugs
7.7. PCSK9 Inhibitors
7.8. Statins
8. Cholesterol Lowering Drug Market, by Distribution Channels
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Cholesterol Lowering Drug Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cholesterol Lowering Drug Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cholesterol Lowering Drug Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Amgen Inc.
13.1.2. Anant Pharmaceuticals Pvt. Ltd.
13.1.3. AstraZeneca PLC
13.1.4. Bristol-Myers Squibb Company
13.1.5. Covis Pharma GmbH
13.1.6. Daiichi Sankyo Co., Ltd.
13.1.7. Dr. Reddy’s Laboratories Ltd.
13.1.8. Kowa Company, Ltd.
13.1.9. Merck & Co., Inc.
13.1.10. Novartis AG
13.1.11. Pfizer Inc.
13.1.12. Sanofi
13.1.13. Sun Pharmaceutical Industries Ltd.
13.1.14. Teva Pharmaceutical Industries Ltd.
13.1.15. Viatris Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. CHOLESTEROL LOWERING DRUG MARKET RESEARCH PROCESS
FIGURE 2. CHOLESTEROL LOWERING DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CHOLESTEROL LOWERING DRUG MARKET DYNAMICS
FIGURE 7. CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 8. CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2023 VS 2030 (%)
FIGURE 10. CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
FIGURE 12. CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CHOLESTEROL LOWERING DRUG MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CHOLESTEROL LOWERING DRUG MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings